{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T21:33:08Z","timestamp":1788039188205,"version":"build-2784847793"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T00:00:00Z","timestamp":1770336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T00:00:00Z","timestamp":1771891200000},"content-version":"vor","delay-in-days":18,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-37462-6","type":"journal-article","created":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T01:33:57Z","timestamp":1770341637000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["A real-world, multicentre, epidemiological study in Czech and Slovak adults with spinal muscular atrophy treated with risdiplam"],"prefix":"10.1038","volume":"16","author":[{"given":"Olesja","family":"Parmova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krystof","family":"Prasil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lenka","family":"Mokra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Svoboda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petr","family":"Ridzon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana","family":"Junkerova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Bakosova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarina","family":"Okalova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lenka","family":"Jurikova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Kolnikova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana","family":"Haberlova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,6]]},"reference":[{"key":"37462_CR1","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1007\/s00415-017-8549-1","volume":"264","author":"IEC Verhaart","year":"2017","unstructured":"Verhaart, I. E. C. et al. A multi-source approach to determine SMA incidence and research ready population. J. Neurol. 264, 1465\u20131473. https:\/\/doi.org\/10.1007\/s00415-017-8549-1 (2017).","journal-title":"J. Neurol."},{"key":"37462_CR2","doi-asserted-by":"publisher","first-page":"2120","DOI":"10.1016\/S0140-6736(08)60921-6","volume":"371","author":"MR Lunn","year":"2008","unstructured":"Lunn, M. R. & Wang, C. H. Spinal muscular atrophy. Lancet 371, 2120\u20132133. https:\/\/doi.org\/10.1016\/S0140-6736(08)60921-6 (2008).","journal-title":"Lancet"},{"key":"37462_CR3","unstructured":"European Medicines Agency. Evrysdi \u2013 Summary of Product Characteristics. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/evrysdi (accessed 13 Aug 2025)."},{"key":"37462_CR4","unstructured":"Ministry of Health of the Czech Republic. Notification of the Ministry of Health, Part 11, 2020 (V\u011bstn\u00edk Ministerstva zdravotnictv\u00ed \u010cesk\u00e9 republiky, \u010c\u00e1stka 11, Ro\u010dn\u00edk 2020) [in Czech]."},{"key":"37462_CR5","unstructured":"Roche communication. https:\/\/www.roche.com\/media\/releases\/med-cor-2025-06-04 (accessed 13 Aug 2025)."},{"key":"37462_CR6","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1177\/0883073811420294","volume":"26","author":"AM Glanzman","year":"2011","unstructured":"Glanzman, A. M. et al. Validation of the expanded Hammersmith functional motor scale in spinal muscular atrophy type II and III. J. Child Neurol. 26, 1499\u20131507. https:\/\/doi.org\/10.1177\/0883073811420294 (2011).","journal-title":"J. Child Neurol."},{"key":"37462_CR7","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1002\/mus.25430","volume":"55","author":"ES Mazzone","year":"2016","unstructured":"Mazzone, E. S. et al. Revised upper limb module for spinal muscular atrophy: Development of a new module. Muscle Nerve 55, 869\u2013874. https:\/\/doi.org\/10.1002\/mus.25430 (2016).","journal-title":"Muscle Nerve"},{"key":"37462_CR8","doi-asserted-by":"publisher","first-page":"2586","DOI":"10.1111\/ene.14472","volume":"27","author":"B Stolte","year":"2020","unstructured":"Stolte, B. et al. Minimal clinically important differences in functional motor scores in adults with spinal muscular atrophy. Eur. J. Neurol. 27, 2586\u20132594. https:\/\/doi.org\/10.1111\/ene.14472 (2020).","journal-title":"Eur. J. Neurol."},{"key":"37462_CR9","doi-asserted-by":"publisher","DOI":"10.1111\/ene.70268","volume":"32","author":"G Coratti","year":"2025","unstructured":"Coratti, G. et al. Longitudinal assessment of 4-year HFMSE changes in SMA II and III patients treated with nusinersen. Eur. J. Neurol. 32, e70268. https:\/\/doi.org\/10.1111\/ene.70268 (2025).","journal-title":"Eur. J. Neurol."},{"key":"37462_CR10","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1111\/ene.16309","volume":"31","author":"G Coratti","year":"2024","unstructured":"Coratti, G. et al. Determining minimal clinically important differences in the Hammersmith functional motor scale expanded for untreated spinal muscular atrophy patients: an international study. Eur. J. Neurol. 31, 1351\u20131361. https:\/\/doi.org\/10.1111\/ene.16309 (2024).","journal-title":"Eur. J. Neurol."},{"key":"37462_CR11","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1002\/mus.28327","volume":"71","author":"M Gavriilaki","year":"2024","unstructured":"Gavriilaki, M., Moschou, M., Pagiantza, M., Arnaoutoglou, M. & Kimiskidis, V. Risdiplam in adult patients with 5q spinal muscular atrophy: A single-center longitudinal study. Muscle Nerve 71, 384\u2013391. https:\/\/doi.org\/10.1002\/mus.28327 (2024).","journal-title":"Muscle Nerve"},{"key":"37462_CR12","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1002\/mus.27804","volume":"67","author":"NCN Garz\u00f3n","year":"2023","unstructured":"Garz\u00f3n, N. C. N., Castellano, I. P., Sevilla, T. & V\u00e1zquez-Costa, J. F. Risdiplam in non-sitter patients aged 16 years and older with 5q spinal muscular atrophy. Muscle Nerve 67, 407\u2013411. https:\/\/doi.org\/10.1002\/mus.27804 (2023).","journal-title":"Muscle Nerve"},{"key":"37462_CR13","doi-asserted-by":"publisher","first-page":"75","DOI":"10.3233\/JND-230197","volume":"11","author":"B Sitas","year":"2024","unstructured":"Sitas, B., Hancevic, M., Bilic, K., Bilic, H. & Bilic, E. Risdiplam real-world data: Looking beyond motor neurons and motor function measures. J. Neuromuscul. Dis. 11, 75\u201384. https:\/\/doi.org\/10.3233\/JND-230197 (2024).","journal-title":"J. Neuromuscul. Dis."},{"key":"37462_CR14","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1186\/s13023-024-03442-0","volume":"19","author":"G Severa","year":"2024","unstructured":"Severa, G. et al. Risdiplam: Therapeutic effects and tolerability in a small cohort of 6 adult type 2 and type 3 SMA patients. Orphanet J. Rare Dis. 19, 430. https:\/\/doi.org\/10.1186\/s13023-024-03442-0 (2024).","journal-title":"Orphanet J. Rare Dis."},{"key":"37462_CR15","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000203892","author":"A Shivaprasad","year":"2023","unstructured":"Shivaprasad, A. et al. Single-center experience of nusinersen and risdiplam in adult SMA patients (P2\u20138.015). Neurology https:\/\/doi.org\/10.1212\/WNL.0000000000203892 (2023).","journal-title":"Neurology"},{"key":"37462_CR16","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000203570","author":"L Servais","year":"2023","unstructured":"Servais, L. et al. SUNFISH Parts 1 and 2: 4-year efficacy and safety data of risdiplam in types 2 and 3 spinal muscular atrophy (SMA) (S34.009). Neurology https:\/\/doi.org\/10.1212\/WNL.0000000000203570 (2023).","journal-title":"Neurology"},{"key":"37462_CR17","doi-asserted-by":"publisher","first-page":"4871","DOI":"10.1007\/s00415-024-12318-z","volume":"271","author":"CA Chiriboga","year":"2024","unstructured":"Chiriboga, C. A. et al. JEWELFISH: 24-month results from an open-label study in non-treatment-na\u00efve patients with SMA receiving treatment with risdiplam. J. Neurol. 271, 4871\u20134884. https:\/\/doi.org\/10.1007\/s00415-024-12318-z (2024).","journal-title":"J. Neurol."},{"key":"37462_CR18","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1007\/s00415-023-11560-1","volume":"270","author":"M Oskoui","year":"2023","unstructured":"Oskoui, M. et al. Two-year efficacy and safety of risdiplam in patients with type 2 or non-ambulant type 3 spinal muscular atrophy. J. Neurol. 270, 2531\u20132546. https:\/\/doi.org\/10.1007\/s00415-023-11560-1 (2023).","journal-title":"J. Neurol."},{"key":"37462_CR19","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s12883-024-03562-x","volume":"24","author":"B Bjelica","year":"2024","unstructured":"Bjelica, B. et al. Risdiplam therapy in adults with 5q-SMA: Observational study on motor function and treatment satisfaction. BMC Neurol. 24, 67. https:\/\/doi.org\/10.1186\/s12883-024-03562-x (2024).","journal-title":"BMC Neurol."},{"key":"37462_CR20","doi-asserted-by":"publisher","first-page":"2649","DOI":"10.1007\/s00415-024-12203-9","volume":"271","author":"S Brakemeier","year":"2024","unstructured":"Brakemeier, S., Lipka, J., Schlag, M., Kleinschnitz, C. & Hagenacker, T. Risdiplam improves subjective swallowing quality in non-ambulatory adult patients with 5q-spinal muscular atrophy despite advanced motor impairment. J. Neurol. 271, 2649\u20132657. https:\/\/doi.org\/10.1007\/s00415-024-12203-9 (2024).","journal-title":"J. Neurol."},{"key":"37462_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2025.105397","volume":"52","author":"L Iterbeke","year":"2025","unstructured":"Iterbeke, L. & Claeys, K. G. Two-year risdiplam treatment in adults with spinal muscular atrophy: Improvements in motor and respiratory function, quality of life and fatigue. Neuromuscul. Disord. 52, 105397. https:\/\/doi.org\/10.1016\/j.nmd.2025.105397 (2025).","journal-title":"Neuromuscul. Disord."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-37462-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-37462-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-37462-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T00:09:06Z","timestamp":1771978146000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-37462-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,6]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["37462"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-37462-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,6]]},"assertion":[{"value":"31 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The REaDY registry and the present study were approved by the Multicenter Ethics Committee, Czechia, acting as the central ethics committee for nationwide registries, and by the local Independent Ethics Committees of all participating centres. These included: the Ethics Committee of the Charles University Hospital Motol and the 2nd Faculty of Medicine, Charles University in Prague; the Ethics Committee of the University Hospital Brno; the Ethics Committee of the University Hospital Ostrava; and the Ethics Committee of the Institute for Clinical and Experimental Medicine and the Thomayer University Hospital. For participating centres in Slovakia, approval was granted by the Ethics Committee of the National Institute of Children\u2019s Diseases and the Multicenter Ethics Committee, Slovakia. Corresponding approval numbers and dates are provided in the Supplementary Material. The study was conducted in accordance with the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"7549"}}